This pharmaceutical-grade Spiramycin Base is a 16-membered macrolide antibiotic distinguished by its exceptional tissue penetration and intracellular concentration in macrophages. It is the first-line agent for preventing congenital toxoplasmosis transmission during pregnancy, a niche indication where its well-established safety profile gives it a decisive clinical advantage over alternative therapies.
| CAS Number | 8025-81-8 |
|---|---|
| Molecular Formula | C43H74N2O14 (Spiramycin I, major component) |
| Molecular Weight | 843.05 (Spiramycin I) |
| Pharmacopoeia | EP/CEP |
| Packaging | 25 KG/DRUM |
Spiramycin Base is a 16-membered macrolide antibiotic produced by Streptomyces ambofaciens. It is widely used in human medicine for its excellent tissue penetration and intracellular concentration, particularly in the treatment of toxoplasmosis during pregnancy.
Spiramycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It achieves high tissue concentrations, especially in the respiratory tract, and concentrates in macrophages. It is a well-established antibacterial agent.
| Purity | As per EP monograph |
|---|---|
| Residual Solvents | Compliant with ICH Q3C |
| Heavy Metals | Compliant with pharmacopoeia limits |
| GMP Status | Manufactured under GMP conditions |